Product(s) used in this publication: PepMix™ Peptide Pools
Background: Understanding the memory T-cell response to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is crucial for assessing the longevity of protective immunity after SARS-CoV-2 infection or coronavirus disease-2019 (COVID-19) vaccination. However, the longitudinal memory T-cell response up to 8 months post-symptom onset (PSO) according to the severity of illness is unknown.
Methods: We analyzed peripheral blood mononuclear cells (PBMCs) from healthy volunteers or patients with COVID-19 who experienced asymptomatic, mild, or severe illness at 2, 5, and 8 months PSO. SARS-CoV-2 spike, nucleocapsid, and membrane protein-stimulated PBMCs were subjected to flow cytometry analysis.
Results: A total of 24 patients-seven asymptomatic and nine with mild and eight with severe disease-as well as six healthy volunteers were analyzed. SARS-CoV-2-specific OX40 +CD137 + CD4 + T cells and CD69 +CD137 + CD8 + T cells persisted at 8 months PSO. Also, antigen-specific cytokine-producing or polyfunctional CD4 + T cells were maintained for up to 8 months PSO. Memory CD4 + T-cell responses tended to be greater in patients who had severe illness than in those with mild or asymptomatic disease.
Conclusions: Memory response to SARS-CoV-2, based on the frequency and functionality, persists for 8 months PSO. Further investigations involving its longevity and protective effect from reinfection are warranted.